AstraZeneca Targets $1.5 Billion in Annual Savings by 2029
AstraZeneca plans to save $1.5 billion a year by 2029 through a restructuring program aimed primarily at funding drug development. The company also reported…
AstraZeneca targets $1.5 billion in annual savings by 2029 through a restructuring program announced Friday, as the drugmaker reported third-quarter revenue of $16.21 billion. The company said the savings will primarily fund drug development; the plan could also involve up to $2 billion in one-time restructuring costs.
The results included a 7% rise in revenue and a 17% increase in core earnings per share to $2.79. AstraZeneca reiterated its full-year 2026 guidance, keeping its expectations for revenue and core earnings growth unchanged.
What will AstraZeneca’s savings plan fund?
The company said the restructuring is intended primarily to support drug development. Its target is $1.5 billion in annual savings by 2029, while one-time restructuring costs could reach $2 billion.
The savings target comes as AstraZeneca points to a large development pipeline and upcoming clinical trial results. The company has more than 180 projects in development, spanning experimental treatments for cancer, respiratory illnesses and rare diseases.
Chief Executive Pascal Soriot said results from trials expected in 2027 could lead to peak annual sales of more than $20 billion. That is a potential sales figure tied to the upcoming readouts, not revenue already generated by the company.
“Our rich series of upcoming readouts in 2027 has a potential of more than twenty billion dollars,” Soriot said. He added that AstraZeneca had multiple potential blockbuster medicines in late-stage development and said the company remained on track to deliver its 2030 ambition and sustain growth through the next decade.
Quarterly results show growth in cancer drugs
AstraZeneca’s third-quarter revenue reached $16.21 billion, above estimates of about $16 billion. Core earnings per share rose to $2.79, compared with consensus estimates of $2.59.
Oncology revenue climbed 17% to $7.77 billion, supported by sales growth for Enhertu and Imfinzi. The increase in cancer-drug revenue helped drive the overall quarterly performance.
Not every product moved in the same direction. Sales of Farxiga, a diabetes drug, fell 25% to $1.61 billion amid growing generic competition. The contrasting figures show why AstraZeneca’s pipeline and investment plans matter to its business: established products can face pressure even as other treatment areas expand.
For patients and the wider health sector, the restructuring links cost savings directly to the company’s stated priority of developing medicines. The plan’s effect will depend on how the company carries it out and how its development projects progress; the announced target sets the scale of savings, not the outcome of individual trials.
AstraZeneca keeps 2026 guidance
The drugmaker expects full-year 2026 revenue to grow by a mid-to-high single-digit percentage and core earnings per share to increase by a low double-digit percentage at constant exchange rates. It reiterated those expectations alongside its quarterly results.
Soriot’s comments put attention on the potential value of the 2027 trial readouts, while the restructuring sets a savings target for 2029. The company’s stated sales potential from those readouts exceeds $20 billion in peak annual revenue.
